Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 16, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details specific transfers of Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991:
- May 12, 2006: Transfer of 38,548 Ordinary Shares.
- May 15, 2006: Transfer of 32,322 Ordinary Shares.
- May 16, 2006: Transfer of 28,327 Ordinary Shares.
These transactions were advised to the Company on May 16, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held by the GSK Trust in the same capacity as other employees. No specific risks, contingencies, or unusual items regarding financial operations are disclosed in this text.
Key Facts for Investor Verification
- Verify the total number of shares transferred to the SmithKline Beecham Employee Share Option Plan 1991 during the reporting week (99,197 shares).
- Confirm the status of the GSK Trust as a discretionary trust for employee beneficiaries.
- Note that the filing does not contain financial results; investors should refer to Form 20-F or quarterly reports for financial metrics.